ArticleJournal of pharmaceutical health care and sciences2025
Postoperative D-dimer as a signal of venous thromboembolism in patients receiving Edoxaban after hip or knee arthroplasty.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEdoxaban is the only direct-acting oral anticoagulant (DOAC) indicated for preventing venous thromboembolism (VTE) in patients undergoing arthroplasty and can be administered for a short period (1-2 weeks). The dosage of edoxaban is set according to renal function and the presence or absence of concomitant medications with P-glycoprotein inhibitory effects. However, a small number of patients still develop VTE after lower-extremity orthopedic surgery (LE-OS), despite edoxaban administration. This single-center, exploratory cohort study retrospectively investigated patients prescribed edoxaban after LE-OS in order to explore the potential of D-dimer as a signal of VTE.
methodsOf the 1,457 patients who received edoxaban after total hip arthroplasty or total knee arthroplasty between January 2016 and December 2020, 1,244 who cleared the exclusion criteria were divided into the non-VTE group (1,219 patients) and VTE group (25 patients). To reduce bias in VTE occurrence, patient age, sex, body weight, serum creatinine, edoxaban underdosing, previous thromboembolism, bed rest duration ≥ 48 h, and blood transfusion were matched using propensity score matching (PSM). We compared the routinely measured D-dimer values of blood samples collected on postoperative day 7 among non-VTE and VTE groups using the Mann-Whitney U test.
resultsAfter PSM, there were 23 patients in each of the non-VTE and VTE groups. The median (interquartile range) D-dimer value on postoperative day 7 was 6.2 (4.2-8.1) µg/mL in the non-VTE group and 9.6 (6.3-12.4) µg/mL in the VTE group (p = 0.005).
conclusionsThis retrospective exploratory study demonstrated that D-dimer values in patients receiving edoxaban after LE-OS may serve as a signal for VTE occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.